Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Terminated
2(33%)

Phase Distribution

Ph early_phase_1
1
17%
Ph phase_1
4
67%
Ph phase_2
1
17%

Phase Distribution

5

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Early Phase 1First-in-human
1(16.7%)
Phase 1Safety & dosage
4(66.7%)
Phase 2Efficacy & side effects
1(16.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

25.0%

1 of 4 finished

Non-Completion Rate

75.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(1)
Terminated(3)
Other(2)

Detailed Status

unknown2
Terminated2
Completed1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
33.3%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (16.7%)
Phase 14 (66.7%)
Phase 21 (16.7%)

Trials by Status

completed117%
unknown233%
withdrawn117%
terminated233%

Recent Activity

0 active trials
Showing 5 of 6
terminatedphase_1

Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer

NCT05618613
withdrawnphase_1

A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer

NCT06938711
terminatedphase_2

Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)

NCT04738292
completedearly_phase_1

Onapristone as Preoperative Treatment for Postmenopausal Women With Hormone Receptor + and HER2- Breast Cancer

NCT04142892
unknownphase_1

Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers

NCT02052128
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT05618613Phase 1

Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer

Terminated
NCT06938711Phase 1

A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer

Withdrawn
NCT04738292Phase 2

Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)

Terminated
NCT04142892Early Phase 1

Onapristone as Preoperative Treatment for Postmenopausal Women With Hormone Receptor + and HER2- Breast Cancer

Completed
NCT02052128Phase 1

Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers

Unknown
NCT02049190Phase 1

Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer

Unknown

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6